← Eichor
Condition: Sclc Extensive Stage Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Sclc Extensive Stage

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Radiotherapy to All Residual Lesions After Chemoimmunotherapy
Phase 1/Phase 2 · 1 location(s) · Anhui Provincial Hospital · NCT06479473Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Ot
Phase 1/Phase 2 · 33 location(s) · Novartis Pharmaceuticals · NCT06726148Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480213Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
Phase 2 · 2 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07110103SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
Phase 1/Phase 2 · 1 location(s) · SN BioScience · NCT07391813Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Phase 1/Phase 2 · 17 location(s) · Genprex, Inc. · NCT05703971Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Tr
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT06698965Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
NA · 2 location(s) · Yunpeng Liu · NCT06480864A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Phase 1/Phase 2 · 4 location(s) · Novartis Pharmaceuticals · NCT07564401A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase 1 · 6 location(s) · Chugai Pharmaceutical · NCT07107490A Study of Ivonescimab in First-Line ES-SCLC
Phase 2 · 3 location(s) · Akeso · NCT07245446Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
Phase 2 · 5 location(s) · Universität des Saarlandes · NCT06223711Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · 148 location(s) · SWOG Cancer Research Network · NCT06769126DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroen
Phase 2 · 59 location(s) · Boehringer Ingelheim · NCT05882058A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligo
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06177925Second-line Immunotherapy for ES-SCLC
NA · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06853678Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
Phase 1 · 1 location(s) · University of Texas Southwestern Medical Center · NCT07139990Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small
Phase 2/Phase 3 · 416 location(s) · National Cancer Institute (NCI) · NCT04402788DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop
Phase 3 · 242 location(s) · Boehringer Ingelheim · NCT07472517A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Th
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07358676Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
Phase 2 · 2 location(s) · University of Chicago · NCT05068232A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in Fi
Phase 3 · 164 location(s) · Amgen · NCT07005128Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Phase 2 · 1 location(s) · Guangzhou Institute of Respiratory Disease · NCT06739928A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combinati
Phase 2 · 61 location(s) · AbbVie · NCT07155174Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients
Phase 1 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07366658Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Phase 1 · 3 location(s) · Emory University · NCT05244239Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06769971A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relaps
Phase 1/Phase 2 · 12 location(s) · Bristol-Myers Squibb · NCT07325136Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Phase 4 · 1 location(s) · Pharmacosmos A/S · NCT05874401PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06429696
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.